Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques [Anaplastic thyroid carcinoma : new therapeutic approaches]
Details
Download: 34009754.pdf (421.15 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_E0FB351F6891
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Carcinome anaplasique de la thyroïde : nouvelles approches thérapeutiques [Anaplastic thyroid carcinoma : new therapeutic approaches]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
19/05/2021
Peer-reviewed
Oui
Volume
17
Number
739
Pages
962-966
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
Anaplastic thyroid cancer (ATC) is among the most aggressive cancers with a median overall survival of 4 months and a disease-specific mortality of close to 100%. As soon as the diagnosis is suspected or established, urgent referral to an experienced multidisciplinary center is imperative. Chemotherapy has limited efficacy. Molecular analyses, together with the availability of novel targeted therapies and immunotherapies, now permit to improve outcomes. In particular, targeted therapy with dabrafenib and trametinib is indicated as first-line therapy for BRAF V600E-mutated ATC.
Keywords
Humans, Mutation, Proto-Oncogene Proteins B-raf/genetics, Thyroid Carcinoma, Anaplastic/diagnosis, Thyroid Carcinoma, Anaplastic/drug therapy, Thyroid Carcinoma, Anaplastic/genetics, Thyroid Neoplasms/diagnosis, Thyroid Neoplasms/drug therapy, Thyroid Neoplasms/genetics
Pubmed
Create date
31/05/2021 9:55
Last modification date
21/11/2022 9:25